PL1660095T3 - Tricykliczne inhibitory PARP - Google Patents

Tricykliczne inhibitory PARP

Info

Publication number
PL1660095T3
PL1660095T3 PL04743516T PL04743516T PL1660095T3 PL 1660095 T3 PL1660095 T3 PL 1660095T3 PL 04743516 T PL04743516 T PL 04743516T PL 04743516 T PL04743516 T PL 04743516T PL 1660095 T3 PL1660095 T3 PL 1660095T3
Authority
PL
Poland
Prior art keywords
parp inhibitors
tricyclic
lactam
relates
tricyclic parp
Prior art date
Application number
PL04743516T
Other languages
English (en)
Inventor
Thomas Helleday
Nicola Curtin
Original Assignee
Cancer Research Tech Ltd
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0317466.1A external-priority patent/GB0317466D0/en
Priority claimed from GB0408524A external-priority patent/GB0408524D0/en
Application filed by Cancer Research Tech Ltd, Pfizer filed Critical Cancer Research Tech Ltd
Publication of PL1660095T3 publication Critical patent/PL1660095T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
PL04743516T 2003-07-25 2004-07-23 Tricykliczne inhibitory PARP PL1660095T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0317466.1A GB0317466D0 (en) 2003-07-25 2003-07-25 Use
GB0408524A GB0408524D0 (en) 2004-04-16 2004-04-16 Use
EP04743516A EP1660095B1 (en) 2003-07-25 2004-07-23 Tricyclic parp inhibitors
PCT/GB2004/003183 WO2005012305A2 (en) 2003-07-25 2004-07-23 Tricyclic parp inhibitors

Publications (1)

Publication Number Publication Date
PL1660095T3 true PL1660095T3 (pl) 2010-07-30

Family

ID=34117642

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04743516T PL1660095T3 (pl) 2003-07-25 2004-07-23 Tricykliczne inhibitory PARP

Country Status (22)

Country Link
US (2) US7531530B2 (pl)
EP (1) EP1660095B1 (pl)
JP (2) JP5466814B2 (pl)
KR (1) KR101138471B1 (pl)
AT (1) ATE454893T1 (pl)
AU (1) AU2004261462B2 (pl)
BR (1) BRPI0412899B1 (pl)
CA (1) CA2533332C (pl)
CY (1) CY1110335T1 (pl)
DE (1) DE602004025123D1 (pl)
DK (1) DK1660095T3 (pl)
ES (1) ES2339663T3 (pl)
IL (1) IL173336A (pl)
MX (1) MXPA06000993A (pl)
NO (1) NO334610B1 (pl)
NZ (1) NZ544989A (pl)
PL (1) PL1660095T3 (pl)
PT (1) PT1660095E (pl)
RU (1) RU2404183C2 (pl)
SI (1) SI1660095T1 (pl)
WO (1) WO2005012305A2 (pl)
ZA (1) ZA200600679B (pl)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030020488A (ko) * 2001-08-29 2003-03-10 강정훈 대나무 추출물을 유효성분으로 하는 화상치료용 조성물
JP2006522088A (ja) * 2003-03-31 2006-09-28 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
MXPA06000993A (es) 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
SG150548A1 (en) * 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
CA2581025C (en) * 2004-09-22 2011-06-07 Pfizer Inc. Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
JP2008513435A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
CA2595290C (en) 2005-01-19 2013-06-25 Mgi Gp, Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
EP1906948A4 (en) 2005-07-18 2010-03-17 Bipar Sciences Inc TREATMENT OF CANCER
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
AU2007292306A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
SI2209375T1 (sl) 2007-10-03 2014-12-31 Eisai Inc. Spojine inhibitorja PARP in metode uporabe
WO2009064738A2 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
AU2008321382A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
ES2607806T5 (es) 2010-02-12 2024-10-07 Pfizer Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
EP3327148B1 (en) 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
EP2646428B1 (en) 2010-12-02 2016-06-01 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivatives, preparation processes and medical uses thereof
US20140051737A1 (en) * 2011-05-10 2014-02-20 Universite Laval Methods for the treatment and diagnostic of pulmonary arterial hypertension
ES2768344T3 (es) 2011-06-17 2020-06-22 Myriad Genetics Inc Métodos y materiales para evaluar el desequilibrio alélico
MX368261B (es) 2011-07-22 2019-09-25 Pacylex Pharmaceuticals Inc Letalidad sintetica y el tratamiento de cancer.
JP6325453B2 (ja) 2011-12-21 2018-05-16 ミリアド・ジェネティックス・インコーポレイテッド ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
ES2687024T3 (es) 2012-02-23 2018-10-23 Children's Medical Center Corporation Procedimientos para predecir la respuesta contra el cáncer
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
EP2892344A1 (de) * 2012-09-05 2015-07-15 Bayer CropScience AG Verwendung substituierter benzodiazepinone und benzazepinone oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
DK2981624T3 (da) 2013-04-05 2020-03-02 Myriad Genetics Inc Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling
CA2931181C (en) 2013-12-09 2023-01-24 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
DK3686288T3 (da) 2014-08-15 2023-05-22 Myriad Genetics Inc Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens
KR20170043597A (ko) 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제
KR20160116831A (ko) 2015-03-31 2016-10-10 (주)아모레퍼시픽 코지산 유도체를 유효성분으로 포함하는 장수 유전자 활성화용 조성물
EP3325662B1 (en) 2015-07-17 2023-08-30 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
US20190055563A1 (en) * 2015-10-19 2019-02-21 Dana-Farber Cancer Institute, Inc. Polymerase q as a target in hr-deficient cancers
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
CN119185322A (zh) 2015-11-20 2024-12-27 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
AU2017240747B2 (en) 2016-04-01 2021-10-21 Sionic Energy, Inc. Modified ionic liquids containing phosphorus
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
AU2017355402A1 (en) 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
US12121518B2 (en) 2017-03-09 2024-10-22 The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College PARP-1 and methods of use thereof
WO2018165615A1 (en) 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
WO2019018432A1 (en) 2017-07-17 2019-01-24 NOHMs Technologies, Inc. ELECTROLYTES CONTAINING PHOSPHORUS
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
EP3752149A4 (en) 2018-02-15 2022-03-02 Senhwa Biosciences, Inc. QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
KR20210097124A (ko) 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
KR20220035925A (ko) 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
CN114072410B (zh) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 作为parp抑制剂吲哚并七元酰肟化合物
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
EP4141127B1 (en) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
EP4532493A1 (en) 2022-06-01 2025-04-09 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2183655C (en) * 1994-02-23 2001-03-06 Lee D. Arnold 4-polycyclic amino-substituted quinazoline derivatives
EP1140936B1 (en) * 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2006522088A (ja) * 2003-03-31 2006-09-28 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
MXPA06000993A (es) 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
SG150548A1 (en) * 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
JP2008513435A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物

Also Published As

Publication number Publication date
KR101138471B1 (ko) 2012-04-25
EP1660095A2 (en) 2006-05-31
IL173336A (en) 2014-02-27
ZA200600679B (en) 2011-08-31
ATE454893T1 (de) 2010-01-15
AU2004261462A1 (en) 2005-02-10
BRPI0412899B1 (pt) 2021-10-05
RU2404183C2 (ru) 2010-11-20
US20070072841A1 (en) 2007-03-29
US7351701B2 (en) 2008-04-01
JP2012087135A (ja) 2012-05-10
WO2005012305A2 (en) 2005-02-10
KR20060066067A (ko) 2006-06-15
DE602004025123D1 (en) 2010-03-04
IL173336A0 (en) 2006-06-11
HK1084602A1 (en) 2006-08-04
CY1110335T1 (el) 2015-01-14
DK1660095T3 (da) 2010-05-25
JP5466814B2 (ja) 2014-04-09
US7531530B2 (en) 2009-05-12
NO334610B1 (no) 2014-04-22
WO2005012305A3 (en) 2005-04-07
US20050143370A1 (en) 2005-06-30
CA2533332A1 (en) 2005-02-10
SI1660095T1 (sl) 2010-05-31
JP5580280B2 (ja) 2014-08-27
RU2006105652A (ru) 2006-08-10
ES2339663T3 (es) 2010-05-24
AU2004261462B2 (en) 2010-04-22
NO20060928L (no) 2006-02-24
BRPI0412899A (pt) 2006-10-03
CA2533332C (en) 2012-01-10
JP2007533601A (ja) 2007-11-22
PT1660095E (pt) 2010-04-19
NZ544989A (en) 2009-10-30
MXPA06000993A (es) 2006-08-31
EP1660095B1 (en) 2010-01-13

Similar Documents

Publication Publication Date Title
SI1660095T1 (sl) Triciklični parp inhibitorji
WO2002044183A3 (en) Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
TW200407322A (en) Novel imidazopyridines as cyclin dependent kinase inhibitors
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
HUP0500574A3 (en) Acridone inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use
IL187382A0 (en) Bicyclic derivatives as modulators of ion channels
TW200740803A (en) Heterocyclic derivatives as modulators of ion channels
SG145695A1 (en) Pyridyl derivatives and their use as therapeutic agents
HUP0501182A2 (hu) Metalloproteáz inhibitorként hatásos aza-spiro-alkán-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
ZA200706029B (en) Tricyclic &-opioid domulators
MXPA03008045A (es) Nuevas composiciones de medicamentos en base a agentes anticolinergicos e inhibidores de pde-iv.
PL1641803T3 (pl) Pochodne tienopirymidyny jako inhibitory kanału potasowego
AP2001002211A0 (en) Tricyclic inhibitors of ply (adp-robose) polymerases
HUP0203288A3 (en) Pyrrole derivatives as phosphodiesterase vii inhibitors, pharmaceutical compositions containing them and their use
AU2003226724A1 (en) Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
HUP0203245A3 (en) Imidazopyridine derivatives as phosphodiesterase vii inhibitors and pharmaceutical compositions containing them
MY136840A (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
EP1244452A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
MXPA05012953A (es) Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
WO2002011732A8 (en) Novel bicyclic and tricyclic pyrrolidine derivatives as gnrh antagonists
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
HUP0301173A3 (en) Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme
HUP0400546A3 (en) Tricyclic derivatives of indole with antiangiogenic activity and pharmaceutical compositions containing them